The Neuro-Urological Connection

Slides:



Advertisements
Similar presentations
Figure 10.6 Structure of the Neuromuscular Junction Process Diagrams Step-by-Step Copyright © 2007 by John Wiley & Sons, Inc.
Advertisements

1 Copyright © 2014 Elsevier Inc. All rights reserved. Chapter 29 Lower Urinary Tract Dysfunction and the Nervous System Amit Batla and Jalesh N. Panicker.
Nervous Systems Part 3 RA # 4.3. What is a synapse?  Gaps between neurons or between neurons and effectors.
Molecular Motors in Neurons: Transport Mechanisms and Roles in Brain Function, Development, and Disease Nobutaka Hirokawa, Shinsuke Niwa, Yosuke Tanaka.
Pascal Rischmann  European Urology Supplements 
Volume 49, Issue 1, Pages (January 2006)
Volume 50, Issue 1, Pages (July 2006)
Prostate Cancer 2008: Challenges in Diagnosis and Management
Turning off Neurotransmitters
Volume 49, Issue 1, Pages (January 2006)
Bladder Cancer: Management and Future Directions
Martin C. Michel  European Urology Supplements 
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
Cholinergic Innervation and Muscarinic Receptors in the Human Prostate
Bladder Cancer: A Major Public Health Issue
François Giuliano, Pierre Clément  European Urology 
Serotonin and the Orchestration of Energy Balance
Long-Term Management of Overactive Bladder with Antimuscarinic Agents
Martin C. Michel, Cees Korstanje, Walter Krauwinkel, Mirjam Kuipers 
A Novel Treatment of Premature Ejaculation
Transmission of Action Potential Across a Synapse
Volume 47, Issue 5, Pages (May 2005)
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
An Update of Current Practice in Hypospadias Surgery
Treatment of Bacterial Urinary Tract Infections: Presence and Future
Richard C. Harkaway  European Urology Supplements 
AP Biology Nervous Systems Part 3.
Volume 51, Issue 1, Pages (January 2007)
Philip Toozs-Hobson, Pallavi Latthe  European Urology Supplements 
Yong-jiang Hei  European Urology Supplements 
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Long-Term Hormonal Therapy: Who Would Benefit?
Nicholas D. James, Jim W. Growcott  European Urology Supplements 
Sergio Bracarda  European Urology Supplements 
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Pharmacotherapy in Stress and Mixed Incontinence
European Urology is “Your” Journal
Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma  Fred Saad  European Urology.
AP Biology Nervous Systems Part 3.
Preclinical Profile of Zoledronic Acid in Prostate Cancer Models
Prostate Cancer 2008: Challenges in Diagnosis and Management
Understanding the Role of Botulinum Toxin A in the Treatment of the Overactive Bladder—More than Just Muscle Relaxation  Apostolos Apostolidis, Axel Haferkamp,
Martin Michel, Jean de la Rosette  European Urology Supplements 
Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer  P. Mongiat-Artus, P. Teillac 
The European Online Sexual Survey (EOSS): Pan-European Perspectives on the Impact of Premature Ejaculation and Treatment-Seeking Behavior  John Dean 
Richard Berges  European Urology Supplements 
The Burden of Stress Urinary Incontinence
Bob Djavan  European Urology Supplements 
Reducing antibiotic use in influenza: challenges and rewards
Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid  Theresa A. Guise,
New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men
Androgen Receptor Mediated Growth of Prostate (Cancer)
The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients  Kurt Miller  European Urology Supplements  Volume.
Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation  Martin.
The Impact of Tamsulosin Oral Controlled Absorption System (OCAS) on Nocturia and the Quality of Sleep: Preliminary Results of a Pilot Study  Bob Djavan,
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Testim® Gel: Review of Clinical Data
Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects  Martin C. Michel, Cees Korstanje, Walter.
AP Biology Nervous Systems Part 3.
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Joaquim Bellmunt  European Urology Supplements 
Classification of Mixed Incontinence
The Impact of Premature Ejaculation on Partners and Relationships
Emmanuel Chartier-Kastler, Andrea Tubaro  European Urology Supplements 
Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Jan Roigas  European Urology Supplements 
Michael Marberger  European Urology Supplements 
Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone?  B. Tombal  European Urology.
Presentation transcript:

The Neuro-Urological Connection Martin C. Michel, Matthias Oelke, Stephan L.M. Peters  European Urology Supplements  Volume 4, Issue 1, Pages 18-28 (January 2005) DOI: 10.1016/j.eursup.2004.10.004 Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 1 Proposed model of the role of glutamate, serotonin (5-HT) and noradrenaline (NA) in the control of urethral function at the organ level. Panel A: Storage phase. Activity of the pudendal nerve is primarily controlled in the sacral spinal cord, i.e. Onuf's nucleus, by descending nerve fibres releasing glutamate. Neurones releasing 5-HT or NA act to potentiate the effects of glutamate, resulting in an enhanced tone of the urethral rhabdosphincter. Duloxetine increases synaptic 5-HT and NA concentrations and hence enhances the facilitatory role of 5-HT and NA. Panel B: During voiding glutamate is turned off, eliminating pudendal nerve activity and allowing the urethral rhabdosphincter to relax, even in the presence of duloxetine. (Adapted from Viktrup et al. [70], reproduced with permission of Physicians Postgraduate Press, Inc.). European Urology Supplements 2005 4, 18-28DOI: (10.1016/j.eursup.2004.10.004) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 2 Effect of duloxetine on the synapse of a serotonin (5-HT) releasing neurone at the molecular level. Panel A: Situation in the absence of duloxetine. Released 5-HT is rapidly and efficiently inactivated by reuptake into the neurone releasing it. This limits duration and magnitude of the 5-HT signal. Panel B: In the presence of duloxetine the neuronal 5-HT reuptake mechanism is blocked and hence 5-HT inactivation in the synaptic cleft is markedly reduced. This results in increased and prolonged 5-HT concentrations in the synapse and hence enhanced activation of the post-junctional neurone, e.g. of the motor neurone of the rhabdosphincter originating from Onuf's nucleus in the sacral spinal cord. A similar situation exists for the effect of duloxetine in the synapse of noradrenaline-releasing neurones. (Adapted from Thor [71], reproduced with permission of Elsevier). European Urology Supplements 2005 4, 18-28DOI: (10.1016/j.eursup.2004.10.004) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 3 Effect of duloxetine in cats challenged with trans-vesical acetic acid infusion [64]. Duloxetine administration significantly and dose-dependently increased the EMG activity of the rhabdosphincter muscle (up to 8-fold) and restored bladder capacity to pre-treatment values. Micturition was not adversely affected. European Urology Supplements 2005 4, 18-28DOI: (10.1016/j.eursup.2004.10.004) Copyright © 2004 Elsevier B.V. Terms and Conditions